Dyne Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Dyne Therapeutics, Inc. (DYN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $661.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-02
- Dyne Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $661.00K, a 95.50% decline from fiscal 2024.
- Dyne Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $14.70M, a 1353.71% increase from fiscal 2023.
- Dyne Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2023 was $1.01M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $661.00K 10-K · filed 2026-03-02 |
| 2024-12-31 | $14.70M 10-K · filed 2026-03-02 |
| 2023-12-31 | $1.01M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |